учебник теория государства и права румынина скачать
Главное меню:
Интересное
учебник теория государства и права румынина скачать, MDS prognosis: Outlook and life expectancy - Medical News Today, What Are Myelodysplastic Syndromes? | American Cancer Society, About Myeloid Malignancies | Center for Cancer Research, Distinguishing AML from MDS: a fixed blast percentage may no , What are the Differences Between MDS and AML? - HealthTree, , .
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) are a heterogeneous group of malignant clonal hematopoietic stem cell disorders. MDS is characterized by ineffective hematopoiesis, marrow dysplasia, peripheral blood cytopenia, and a high propensity for transformation into AML. Although several agents that induce partial remissions and prolong survival in MDS patients have been identified, the only potential curative therapy for MDS is an allogeneic hematopoietic stem cell transplant (HSCT) for which most patients are ineligible due to advanced age, progressive disease, or comorbidities. There is also a small but increasingly recognized group of secondary MDS/AML which arises from inherited genetic diseases and evolves into an aggressive leukemia, often in young adulthood (such as those arising from germline mutations in GATA2 or RUNX1) for which pathogenesis and natural histories are poorly understood. A consequence of genotoxic therapy for a primary malignancy is therapy-related MDS/AML, which develops in a fraction of individuals who were cured of their original cancer, harbor high-risk mutations and typically are not sensitive to further chemotherapy., Leukemia is a cancer of the blood-forming tissues. About one-third of people with MDS develop AML, which is cancer of the bone marrow. For this reason, doctors sometimes refer to MDS as preleukemia., Myelodysplastic syndromes (MDS), also known as myelodysplastic neoplasms, are conditions that can occur when the blood-forming cells in the bone marrow become abnormal, resulting in the marrow not making enough healthy new blood cells. This leads to low levels of one or more types of blood cells. MDS is considered a type of cancer..
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) are a heterogeneous group of malignant clonal hematopoietic stem cell disorders. MDS is characterized by ineffective hematopoiesis, marrow dysplasia, peripheral blood cytopenia, and a high propensity for transformation into AML., Patients with acute myeloid leukemia (AML) have conventionally received more intense therapy than patients with myelodysplastic syndrome (MDS). Although less intense therapies are being used more often in AML, the dichotomy between AML and MDS remains, with the presence of ≥20% myeloblasts in marrow or peripheral blood generally regarded as defining AML. Consequently, patients with 19% , In some cases, bone marrow transplantation is considered. Most recent studies are focused on treating high-risk and very high-risk MDS with chemotherapy to extend life expectancy. AML treatment typically involves chemotherapy to destroy the cancer cells., , , .